Congested OTC Monograph Process Can Leave Manufacturers Confused
This article was originally published in The Tan Sheet
Executive Summary
The disparity between FDA's OTC monographs and up-to-date communications from the agency can create confusion for manufacturers, Office of New Drugs Director John Jenkins acknowledges